$2.01
-0.08 (-3.83%)
Open$2.08
Previous Close$2.09
Day High$2.20
Day Low$2.00
52W High$5.83
52W Low$1.22
Volume—
Avg Volume43.4K
Market Cap54.61M
P/E Ratio—
EPS$-1.14
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+1,254.2% upside
Current
$2.01
$2.01
Target
$27.22
$27.22
$16.99
$27.22 avg
$37.92
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 319.2K | 195.8K | 4.38M |
| Net Income | -46,940,540 | -25,913,320 | -1,275,702 |
| Profit Margin | -14,755.4% | -14,017.6% | -29.1% |
| EBITDA | -56,835,359 | -33,118,806 | -1,970,058 |
| Free Cash Flow | — | — | -1,043,157 |
| Rev Growth | +63.0% | +63.0% | +7.3% |
| Debt/Equity | — | — | 0.26 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $266.28 | +0.73% | 74.3 | 468.50B |
| AMGN | Amgen Inc | $418.13 | +0.85% | 25.1 | 219.78B |
| GILD | Gilead Sciences Inc | $152.21 | +0.85% | — | 185.02B |
| VRTX | Vertex Pharmaceuticals Inc | $527.67 | +0.28% | 30.5 | 134.17B |
| REGN | Regeneron Pharmaceuticals | $752.25 | -4.54% | 18.8 | 81.31B |
| ALNY | Alnylam Pharmaceuticals Inc | $255.36 | -0.23% | 41.4 | 33.44B |